(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -15.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Macrogenics's revenue in 2025 is $165,494,000.On average, 4 Wall Street analysts forecast MGNX's revenue for 2025 to be $6,099,476,751, with the lowest MGNX revenue forecast at $2,528,228,120, and the highest MGNX revenue forecast at $9,468,214,309. On average, 3 Wall Street analysts forecast MGNX's revenue for 2026 to be $9,250,976,308, with the lowest MGNX revenue forecast at $6,769,330,791, and the highest MGNX revenue forecast at $13,550,670,666.
In 2027, MGNX is forecast to generate $4,425,347,296 in revenue, with the lowest revenue forecast at $2,631,253,416 and the highest revenue forecast at $6,219,441,175.